Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia
- PMID: 28262227
- DOI: 10.1016/S0049-3848(17)30060-9
Gender-related differences in the outcome of patients with venous thromboembolism and thrombophilia
Abstract
Background: In patients with venous thromboembolism (VTE) and factor V Leiden (FVL) or prothrombin 20210G-A mutation (PTM), the influence of gender on outcome has not been consistently studied.
Methods: We used the RIETE (Registro Informatizado Enfermedad TromboEmbolica) database to assess the existence of gender differences in the rate of VTE recurrences (deep vein thrombosis [DVT] or pulmonary embolism [PE]) or major bleeding during the course of anticoagulation and after its discontinuation in FVL and PTM carriers.
Results: From March 2001 to September 2016, 11,224 VTE patients underwent thrombophilia testing. Of these, 1,563 were FVL carriers (863 men and 700 women) and 1,231 were PTM carriers (659 men and 572 women). During the course of anticoagulant therapy, men with FVL had a 6-fold higher rate of VTE recurrences than major bleeds (31 vs. 5 events). In women with FVL, the rate of VTE recurrences was 2-fold higher (16 vs. 8), as was in men (17 vs. 8) or women (17 vs. 9) with PTM. After discontinuing anticoagulation, men with FVL had a 3-fold higher rate of DVT recurrences than women (hazard ratio [HR]: 3.13; 95% CI: 1.79-5.67), with no differences in PE recurrences. Among patients with PTM, there were no gender differences in the rate of DVT (HR: 1.89; 95% CI: 1.00-3.65) or PE recurrences (HR: 1.82; 95% CI: 0.83-4.12).
Conclusions: During the anticoagulation course, men with FVL are at a much higher risk for VTE recurrences than bleeding. After discontinuing anticoagulation, men with FVL are at an increased risk for DVT recurrences.
Keywords: Factor V Leiden; Gender; Prothrombin 20210G-A polymorphism; Thrombophilia; Venous thromboembolism.
© 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Outcome of Patients with Venous Thromboembolism and Factor V Leiden or Prothrombin 20210 Carrier Mutations During the Course of Anticoagulation.Am J Med. 2017 Apr;130(4):482.e1-482.e9. doi: 10.1016/j.amjmed.2016.11.016. Epub 2016 Dec 14. Am J Med. 2017. PMID: 27986523
-
Homozygous factor V Leiden and double heterozygosity for factor V Leiden and prothrombin mutation.J Thromb Thrombolysis. 2013 Oct;36(3):324-31. doi: 10.1007/s11239-012-0824-5. J Thromb Thrombolysis. 2013. PMID: 23054468 Clinical Trial.
-
Plasminogen activator inhibitor-1 4G/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence.Thromb Haemost. 2015 Nov 25;114(6):1156-64. doi: 10.1160/TH15-01-0031. Epub 2015 Aug 6. Thromb Haemost. 2015. PMID: 26245493
-
The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies.Haematologica. 2007 Aug;92(8):1107-14. doi: 10.3324/haematol.10234. Haematologica. 2007. PMID: 17650440
-
Diagnosis and treatment of venous thromboembolism during pregnancy relate to genetic polymorphism.Vascular. 2025 Feb;33(1):186-191. doi: 10.1177/17085381241240554. Epub 2024 Mar 15. Vascular. 2025. PMID: 38490955 Review.
Cited by
-
Sex as a prognostic factor for mortality in adults with acute symptomatic pulmonary embolism.Cochrane Database Syst Rev. 2025 Mar 20;3(3):CD013835. doi: 10.1002/14651858.CD013835.pub2. Cochrane Database Syst Rev. 2025. PMID: 40110896
-
Three-factorial Genetic Thrombophilia with Recurrent Thrombotic Events in a Saudi Patient: A Case Report.Saudi J Med Med Sci. 2020 Sep-Dec;8(3):217-222. doi: 10.4103/sjmms.sjmms_231_18. Epub 2020 Aug 20. Saudi J Med Med Sci. 2020. PMID: 32952515 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical